PaxMedica, Inc. Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PXMD research report →
Companywww.paxmedica.com
PaxMedica, Inc. , a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis.
- CEO
- Howard J. Weisman
- IPO
- 2022
- Employees
- 6
- HQ
- Tarrytown, NY, US
Price Chart
Valuation
- Market Cap
- $12.63K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.29
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1046.98%
- ROIC
- -415.56%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-18,290,000 · -23.56%
- EPS
- $-11.00 · 61.71%
- Op Income
- $-16,145,000
- FCF YoY
- -77.37%
Performance & Tape
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.56
- Avg Volume
- 834
Get TickerSpark's AI analysis on PXMD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 12, 24 | Weisman Howard J. | other | 2,927 |
| Mar 12, 24 | Sheldon Stephen | other | 3,356 |
| Mar 12, 24 | Rome Zachary | other | 4,904 |
| Mar 12, 24 | LaRochelle Karen | other | 604 |
| Mar 12, 24 | Hough David W. | other | 1,452 |
| Mar 12, 24 | Coelho John F | other | 207 |
| Mar 12, 24 | CASAMENTO CHARLES J | other | 992 |
| Feb 21, 24 | Hough David W. | other | 291 |
| Feb 21, 24 | Sheldon Stephen | other | 243 |
| Jan 29, 24 | Rome Zachary | sell | 811 |
Our PXMD Coverage
We haven't published any research on PXMD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PXMD Report →